Clinical Guides
Dilated Cardiomyopathy
A clinically focused, India-adapted guide to dilated cardiomyopathy covering phenotype confirmation, reversible causes, genetics and family screening, pregnancy, contemporary heart-failure therapy, devices and advanced-care referral.
MedNext Academy | 13 min read
Dilated Cardiomyopathy
A clinically focused, India-adapted guide to dilated cardiomyopathy covering phenotype confirmation, reversible causes, genetics and family screening, pregnancy, contemporary heart-failure therapy, devices and advanced-care referral.
Summary
Dilated cardiomyopathy (DCM) is a myocardial phenotype characterised by left-ventricular or biventricular dilatation and systolic dysfunction that is not explained solely by abnormal loading conditions or coronary artery disease sufficient to cause the impairment. The label describes a phenotype, not a completed aetiological diagnosis. Genetic susceptibility, previous myocarditis, alcohol, cardiotoxic medicines, pregnancy-associated disease, nutritional or endocrine disorders, tachyarrhythmia and systemic illness may act alone or together. A patient may present with exertional breathlessness, congestion, an embolic event, atrial or ventricular arrhythmia, conduction disease, or sudden cardiac arrest; relatives may be detected before symptoms.
Safe care has three parallel tracks: stabilise acute heart failure or dangerous rhythm, define the ventricular phenotype and severity, and investigate causes that alter treatment or family risk. Echocardiography starts structural assessment; cardiac magnetic resonance adds tissue characterisation and scar distribution; coronary evaluation, rhythm monitoring, laboratory tests, a three-generation pedigree and selective genetic testing refine the diagnosis. Disease-modifying heart-failure treatment should be established promptly when reduced ejection fraction is present. An implantable cardioverter-defibrillator or resynchronisation device is chosen from individual arrhythmic risk, ejection fraction, electrical dyssynchrony, genotype and response to therapy rather than chamber size alone. Advanced heart-failure referral must precede irreversible renal, hepatic or right-heart failure. This quarantined draft has been reviewed by the MedNext Clinical Team by the MedNext Clinical Team and is not a substitute for specialist assessment.
How Common Is It?
DCM is an important cause of heart failure, transplantation and sudden death worldwide, but a single prevalence figure is unreliable. Studies differ in whether they count only symptomatic dilatation, include hypokinetic non-dilated phenotypes, use hospital codes, perform cardiac magnetic resonance, or screen relatives. Limited access to echocardiography and genetic services causes under-recognition, while referral-centre cohorts enrich severe or familial disease. Apparent idiopathic cases also shrink when coronary disease, toxins, inflammatory disorders and pathogenic variants are investigated systematically. Men are often diagnosed more frequently, although pregnancy-associated disease and sex-specific penetrance change the clinical distribution. Age at onset varies from childhood to later adult life.
Natural history is similarly heterogeneous. Some patients recover ventricular function after removal of a trigger and comprehensive therapy; others enter remission but retain scar, a pathogenic variant or recurrent vulnerability. Persistent low ejection fraction, right-ventricular dysfunction, extensive fibrosis, recurrent decompensation, ventricular arrhythmia and certain genotypes identify greater risk. Improvement in ejection fraction does not prove cure and is not a reason to stop established disease-modifying treatment without expert review. In India, population-level genetic and imaging data remain incomplete, so extrapolated international estimates should be labelled as such. The clinically useful epidemiology is therefore family and phenotype specific: identify affected relatives, define the substrate, document access constraints and follow change over time instead of quoting a false national precision.
Risk Factors
A three-generation pedigree is central. Ask about DCM, unexplained heart failure, pacemakers or defibrillators at a young age, skeletal myopathy, early atrial fibrillation, conduction block, sudden unexplained death and relatives labelled as having myocarditis or an enlarged heart. Pathogenic variants involving structural, sarcomeric, cytoskeletal, nuclear-envelope, desmosomal and ion-channel genes can show age-dependent and incomplete penetrance. LMNA, FLNC, DSP, PLN, RBM20 and selected other genotypes may confer arrhythmic risk out of proportion to ejection fraction, but a variant of uncertain significance must not be used as a predictive family test or automatic device indication. Genetic counselling should precede and follow testing.
Non-genetic and acquired contributors require the same discipline. Quantify alcohol rather than recording social use; ask about cocaine, methamphetamine, anabolic agents, chemotherapy, immune therapies and unregulated supplements. Review pregnancy and postpartum timing, previous myocarditis, sustained tachycardia, thyroid disease, iron overload, nutritional deficiency, HIV and other systemic infection, autoimmune or granulomatous disease, neuromuscular symptoms and occupational exposures. Hypertension or coronary disease may coexist yet be insufficient to explain the severity. Metabolic disease, sleep apnoea and renal dysfunction worsen heart failure even when they did not initiate DCM. In India, prior antitubercular treatment, herbal or over-the-counter preparations and barriers to medicine continuity should be recorded without assuming causation. A trigger can unmask inherited susceptibility; finding alcohol exposure or pregnancy therefore does not remove the need to consider a familial substrate.
Diagnosis
DCM diagnosis requires confirmation of systolic dysfunction and dilatation, exclusion of sufficient loading or ischaemic causes, and a structured search for aetiology. Acute instability is managed while this work proceeds.
History
Define onset and trajectory of exertional limitation, orthopnoea, paroxysmal nocturnal dyspnoea, oedema, abdominal distension, chest pain, palpitations, presyncope, syncope and thromboembolic symptoms. Ask about infection, inflammatory symptoms, pregnancy timing, cardiotoxic cancer treatment, heart-rate history, alcohol and stimulant exposure, endocrine disease and neuromuscular weakness. Record medicines, adherence, salt and fluid practices and prior imaging. Construct a pedigree covering at least three generations and verify reported diagnoses where possible.
Examination
Record blood pressure in both acute and stable states, pulse rhythm, oxygen saturation, perfusion, mental state and volume status. Assess jugular venous pressure, displacement of the apex, third heart sound, functional mitral or tricuspid regurgitation, pulmonary crepitations, hepatomegaly, ascites and peripheral oedema. Look for muscle wasting, contractures, neuropathy, syndromic features, thyroid signs, iron pigmentation and alcohol-related disease. A quiet examination does not exclude severe electrical risk.
Investigations
Obtain ECG, CBC, electrolytes, renal and liver function, glucose or HbA1c, thyroid testing, iron indices, urinalysis, natriuretic peptide and troponin when clinically indicated. Echocardiography measures biventricular size and function, valves, filling, pulmonary pressure and thrombus. CMR assesses volumes, inflammation, infiltration and late gadolinium enhancement. Evaluate coronary anatomy according to probability. Use ambulatory monitoring for symptoms or arrhythmic risk. Genetic testing should use a validated cardiomyopathy panel with counselling when results can change care for the patient or family. Endomyocardial biopsy is selective when suspected inflammation, infiltration or another diagnosis would alter therapy; it is not routine confirmation of every DCM phenotype.
Differential Diagnosis
Ischaemic cardiomyopathy must be distinguished from DCM because diffuse dysfunction can obscure a coronary distribution and younger age does not exclude anomalous, embolic or premature atherosclerotic disease. Long-standing hypertension, severe aortic or mitral valve disease and congenital lesions can produce secondary dilatation; the loading abnormality must be proportionate to the phenotype before it is accepted as the sole cause. Tachycardia-induced cardiomyopathy is suggested by sustained rapid atrial fibrillation, flutter or another rhythm and by recovery after durable rate or rhythm control, although arrhythmia may also be a consequence of primary DCM. Myocarditis may be acute or leave an inflammatory cardiomyopathy. Cardiac sarcoidosis and arrhythmogenic cardiomyopathy can present with ventricular dysfunction and scar.
Peripartum cardiomyopathy overlaps genetically and phenotypically but is defined by its pregnancy-related setting after alternative causes are excluded. Takotsubo syndrome usually has a different regional pattern and time course. Infiltrative and storage disorders such as amyloidosis, haemochromatosis and Anderson-Fabry disease more often produce hypertrophy or restrictive physiology but can reach a dilated phase. Left-ventricular non-compaction traits require cautious interpretation because prominent trabeculation occurs in healthy people and pregnancy. Endocrine, nutritional, mitochondrial and neuromuscular disorders need clinical clues and targeted tests. HIV-associated disease, Chagas disease after residence in an endemic region, toxin exposure and cancer-therapy injury are contextual diagnoses. Athlete’s remodelling normally preserves function and exercise reserve. The final formulation should separate phenotype, established cause, plausible modifiers and unresolved questions rather than hide uncertainty behind the term idiopathic.
Management
Treat pulmonary oedema, hypoperfusion, shock and dangerous arrhythmia in an acute monitored setting. Intravenous diuresis relieves congestion; oxygen is for hypoxaemia, and vasoactive or mechanical support requires specialist haemodynamic assessment. In stable DCM with reduced ejection fraction, establish the four foundational heart-failure drug classes as tolerated: an angiotensin receptor-neprilysin inhibitor or appropriate renin-angiotensin alternative, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor. Start at clinically appropriate doses, sequence rapidly around blood pressure, renal function, potassium and congestion, and titrate with review rather than waiting months between classes. Continue disease-modifying therapy after apparent recovery because relapse occurs. Treat iron deficiency, hypertension, diabetes, sleep apnoea and other contributors; use rehabilitation and individualised exercise advice once stable.
Remove or control a credible cause: sustained abstinence from cardiotoxic alcohol, durable rhythm management for tachycardia-mediated disease, withdrawal of a culprit medicine with oncology input, endocrine correction, or cause-specific treatment for proven inflammatory or metabolic disease. Empirical immunosuppression is not standard DCM therapy. Anticoagulation is reserved for atrial fibrillation, intracardiac thrombus, systemic embolism or another accepted indication. ICD consideration follows persistent dysfunction despite optimised therapy plus individual scar, genotype, arrhythmia and competing-risk assessment; selected high-risk genetic forms may justify discussion above an ejection fraction of 35%. CRT depends on QRS morphology and duration, rhythm, symptoms and ventricular function. Refractory patients need early evaluation for LV assist support or transplantation. Functional valve intervention is considered only after optimal heart-failure and resynchronisation therapy and Heart Team assessment. Genotype-specific device and rare cause-directed decisions rely substantially on observational evidence and expert consensus, so uncertainty and patient preferences belong in the record.
Prescribing Information
Before each heart-failure medicine, document blood pressure, heart rate, volume status, creatinine or eGFR, potassium, pregnancy potential, interactions and prior intolerance. An ARNI must not overlap with an ACE inhibitor; observe the required washout and avoid both in pregnancy. ACE inhibitors, ARBs, ARNIs and mineralocorticoid receptor antagonists require renal and potassium surveillance. Evidence-based beta-blockers are introduced when the patient is not in shock and severe congestion is controlled; abrupt withdrawal can destabilise heart failure. SGLT2 inhibitors benefit eligible patients regardless of diabetes but require counselling about genital infection, volume depletion, perioperative or fasting interruption and rare ketoacidosis. Loop diuretics are adjusted to congestion and daily weight; they improve symptoms but do not replace prognostic therapy. Digoxin has selected roles and a narrow therapeutic margin, particularly with renal impairment or interacting medicines.
Avoid NSAIDs where possible because sodium retention and kidney injury can precipitate decompensation. Non-dihydropyridine calcium-channel blockers can worsen systolic failure. Routine anticoagulation in sinus rhythm is not justified; when atrial fibrillation or thrombus creates an indication, choice must account for renal function, pregnancy and any valve prosthesis. Amiodarone has thyroid, hepatic, pulmonary, ocular and interaction burdens and should not be a reflex response to ectopy. During pregnancy, ACE inhibitors, ARBs, ARNIs, mineralocorticoid antagonists and SGLT2 inhibitors are generally contraindicated; a Pregnancy Heart Team selects safer vasodilators, beta-blockade and diuresis case by case. Bromocriptine is not routine DCM treatment and, in peripartum cardiomyopathy, needs specialist selection and thrombosis planning. Provide a written titration and sick-day plan, not merely a discharge list.
When to Refer
Refer immediately or transfer to advanced cardiac care for cardiogenic shock, recurrent ventricular tachycardia, resuscitated arrest, high-grade conduction block, rapidly worsening biventricular failure, escalating inotrope requirement, refractory pulmonary oedema, progressive kidney or liver injury, or suspected fulminant myocarditis. Contact an advanced heart-failure centre before repeated admissions or irreversible end-organ dysfunction. Objective triggers include intolerance of foundational therapy because of hypotension or renal dysfunction, persistent severe symptoms, recurrent congestion, very low peak exercise capacity, worsening right-heart function and dependence on intravenous diuretics. Assessment may lead to temporary support, durable LVAD or transplantation; referral is evaluation, not a promise of eligibility.
Specialist cardiomyopathy or inherited-cardiac referral is indicated for familial disease, young onset, skeletal or syndromic features, unexplained conduction disease, ventricular arrhythmia, characteristic CMR scar or a pathogenic variant. Genetics services should coordinate consent, interpretation, cascade testing and surveillance of relatives. Electrophysiology input is needed for sustained arrhythmia, unexplained syncope and ICD or CRT decisions. Cardio-oncology, maternal-cardiology, neuromuscular, metabolic, infectious-disease or immunology input follows the suspected cause. In India, explicitly map affordability and travel for CMR, genetic testing, device follow-up and advanced therapy. A district clinician should not delay referral until every aetiological test is complete. Family screening with ECG and imaging can begin even where molecular testing is unavailable, provided findings and uncertainty are communicated carefully.
Red Flags
Cold extremities, altered mentation, oliguria, rising lactate, hypotension, narrow pulse pressure or worsening acidosis indicate low output and possible cardiogenic shock. Severe breathlessness, hypoxaemia, frothy sputum, rapidly rising jugular venous pressure or new right-sided failure demands urgent reassessment. Electrical red flags include sustained ventricular tachycardia, aborted sudden death, high-grade atrioventricular block, marked conduction delay, recurrent unexplained syncope and frequent complex ventricular ectopy with scar or a high-risk genotype. Chest pain with dynamic ST change or troponin rise remains an acute coronary or myocarditis problem until appropriately evaluated. A new embolic neurological deficit may reflect atrial fibrillation or ventricular thrombus.
Repeated admission, falling sodium, progressive renal or hepatic dysfunction, cachexia, escalating diuretic dose and inability to tolerate disease-modifying medicines signal advanced disease even when resting blood pressure appears acceptable. Fever with an intracardiac device, new murmur or embolic signs raises infective endocarditis rather than routine decompensation. In a pregnant or recently postpartum patient, new orthopnoea, resting tachycardia, hypoxaemia or chest symptoms must not be dismissed as normal pregnancy. A relative’s young sudden death, an LMNA- or FLNC-associated phenotype, or extensive non-ischaemic scar changes the arrhythmic conversation even if ejection fraction is above the conventional primary-prevention threshold. Conversely, chamber size alone does not mandate a device. Every red flag should link to an action: emergency treatment, monitored admission, urgent imaging, rhythm protection, or early transfer.
Indian Clinical Context
India has a wide gradient of access: some centres provide CMR, cardiogenetics, electrophysiology, transplant and mechanical support, while many patients first present where serial biomarkers, high-quality echocardiography or specialist follow-up are limited. A practical tiered pathway starts with ECG, chest radiography, basic laboratory assessment and echocardiography, followed by early transfer for shock, dangerous rhythm or severe dysfunction. Coronary disease, diabetes, hypertension, alcohol exposure, nutritional illness, pregnancy-related disease, HIV and cardiotoxic tuberculosis or cancer treatments may coexist. Endemic infection should not be used to label unexplained DCM without syndrome-specific evidence. Chagas testing is exposure based, not part of a routine Indian panel.
Medicine affordability and continuity can determine outcome. Prescribe generic evidence-based options, explain that diuretic symptom relief is not equivalent to prognostic therapy, simplify dosing, and arrange renal and potassium checks that the patient can actually obtain. Ayushman Bharat, state schemes, public cardiology hospitals and charitable device programmes may support eligible care, but availability is local and should not be promised. Genetic panels may be unaffordable and Indian variant representation remains limited; a negative panel does not exclude heritable disease and a variant of uncertain significance must not label relatives. Clinical family screening remains valuable. International ESC recommendations guide phenotype, genetic and device decisions, but transport, CMR, ICD and transplant constraints require explicit shared decisions. Pregnancy counselling must address maternal risk, teratogenic medicines, inheritance uncertainty and access to a Pregnancy Heart Team before conception where possible.
NMC Competency Mapping
DCM integrates General Medicine outcomes in cardiovascular history, examination, heart failure, ECG interpretation, shock, rational prescribing and referral. A learner should recognise left- and right-sided congestion, distinguish warm from cold perfusion, identify an unstable rhythm, and initiate oxygen only for hypoxaemia, diuresis for congestion and urgent escalation for shock. The learner should interpret an ECG, chest radiograph and echocardiographic report in clinical context; explain why ejection fraction describes function but not aetiology; and construct a differential including coronary, valvular, hypertensive, tachycardia-mediated, inflammatory, toxic, endocrine and pregnancy-associated disease.
At the applied level, the student should obtain a three-generation pedigree, recognise when genetic counselling and family ECG or echocardiography are appropriate, and avoid using a variant of uncertain significance as a diagnosis. Therapeutic competence includes the rationale, contraindications and monitoring for the four foundational HFrEF drug classes, appropriate diuretic use, pregnancy-related restrictions, anticoagulation indications and avoidance of harmful NSAIDs. The learner should explain the distinct purposes of ICD, CRT, LVAD and transplantation, without reducing device choice to one ejection-fraction number. Indian-system competence includes assessing medicine access, arranging feasible biochemical monitoring, communicating referral urgency and identifying public pathways without guaranteeing entitlement. Advanced CMR interpretation, variant classification, biopsy, device implantation and transplant selection remain supervised specialist tasks. Local departments should map these outcomes to current NMC cardiovascular and emergency competencies rather than inventing a DCM-specific code.
Key Exam Pearls for NEET PG
DCM is ventricular dilatation with systolic dysfunction not adequately explained by loading conditions or coronary disease; idiopathic means that a cause has not yet been found. Functional mitral regurgitation, an S3, displaced apex, left bundle-branch block and mural thrombus can accompany the phenotype. Echocardiography defines chamber and valve consequences, whereas CMR measures volumes and identifies non-ischaemic scar, inflammation or infiltrative clues. Coronary assessment remains necessary when probability warrants it. Endomyocardial biopsy is selective and treatment changing, not routine. A negative genetic panel does not exclude inheritance, and a variant of uncertain significance is not suitable for predictive cascade testing. LMNA, FLNC and other selected genotypes can carry important arrhythmic risk before ejection fraction becomes severely reduced.
Foundational HFrEF therapy comprises renin-angiotensin pathway treatment, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor, with diuretics for congestion. Continue disease-modifying treatment when ejection fraction improves unless a specialist gives a compelling reason to change it. Anticoagulation is not routine in sinus rhythm. Primary-prevention ICD assessment generally follows a period of optimised therapy, but scar, genotype, syncope and documented arrhythmia modify risk. CRT is for appropriate electrical dyssynchrony, especially left bundle-branch morphology with a broad QRS, not for mechanical dilatation alone. Pregnancy can decompensate established DCM; renin-angiotensin drugs, mineralocorticoid antagonists and SGLT2 inhibitors are generally avoided. Recurrent admission, end-organ dysfunction and inotrope dependence are prompts for advanced heart-failure referral before transplantation or LVAD becomes impossible.
Frequently Asked Questions
Does an improved ejection fraction mean dilated cardiomyopathy has been cured permanently?
Not necessarily. Recovery may represent remission after treatment or removal of a trigger, while scar, genetic susceptibility and relapse risk remain. Disease-modifying heart-failure therapy is usually continued, with periodic imaging and rhythm review. Stopping medicines solely because one scan improved can precipitate recurrent dysfunction and should require specialist assessment.
Should every person with dilated cardiomyopathy undergo a genetic test?
Genetic evaluation should be considered whenever a result could change the patient’s risk assessment, family surveillance or reproductive counselling, especially with young onset, familial disease, conduction abnormalities or ventricular arrhythmia. Testing needs pre- and post-test counselling. Where testing is unavailable or negative, first-degree relatives may still need ECG and cardiac imaging.
Is an implantable defibrillator automatically required when the ejection fraction is below 35 percent?
No single number makes the decision automatic. Clinicians reassess after comprehensive therapy and consider symptoms, survival expectancy, competing illness, QRS pattern, scar, documented rhythm, syncope and genotype. Some high-risk genetic phenotypes warrant discussion above 35 percent, while severe comorbidity or likely recovery may change timing and net benefit.
Can a woman with dilated cardiomyopathy safely plan a pregnancy?
Risk varies greatly with ventricular function, symptoms, prior decompensation, rhythm, genotype and medicines. Pre-conception assessment by a Pregnancy Heart Team is essential because several standard heart-failure drugs are contraindicated and pregnancy may worsen function. Counselling should cover maternal risk, inheritance, medication transition, surveillance, delivery and postpartum planning before conception.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic